GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹109 Cr | ₹-357 Cr | ₹2,621 Cr | ₹1,270 Cr | ₹2,804 Cr |
What is the latest Total Non-Current Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹109 Cr |
| Mar2024 | ₹-357 Cr |
| Mar2023 | ₹2,621 Cr |
| Mar2022 | ₹1,270 Cr |
| Mar2021 | ₹2,804 Cr |
How is Total Non-Current Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹109 Cr | Positive | |
| Mar2024 | ₹-357 Cr | Negative | |
| Mar2023 | ₹2,621 Cr | 106.48 | |
| Mar2022 | ₹1,270 Cr | -54.72 | |
| Mar2021 | ₹2,804 Cr | - | |
Compare Total Non-Current Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹56,176.1 Cr | -1.4% | 2.2% | 32.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹401,541.0 Cr | -3.6% | -6.8% | -5.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹163,031.0 Cr | -5.4% | -2.4% | 3.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹138,451.0 Cr | 3.6% | 8.5% | 23.5% | Stock Analytics | |
| CIPLA | ₹112,377.0 Cr | -5.1% | -7.1% | -3.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,355.5 Cr | -4.1% | -8.3% | -12.1% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | -1.4% |
2.2% |
32.1% |
| SENSEX | -0.4% |
-1.7% |
9.1% |
You may also like the below Video Courses